Linked Life Data

1693314

Source:http://linkedlifedata.com/resource/pubmed/id/1693314

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1990-7-11
pubmed:abstractText
A series of phase II studies using ifosfamide (IFX) as a single agent and in combination with cisplatin and bleomycin (BIP) in advanced and recurrent cervical cancer have been coordinated at the West Midlands CRC Clinical Trials Unit (Birmingham, UK). The aims of these studies were to identify single agents and combination regimens that may be of value for palliation and have potential for use as neoadjuvant and adjuvant therapy at the time of primary treatment. A total of 79 patients with disease non-amenable to radical local therapy were treated with single-agent IFX or the BIP combination. In 30 patients treated with single-agent IFX, 10 objective responses (30%) were seen, with 1 complete response. In 49 patients treated with BIP, 34 objective responses (69%) were seen, with 10 complete responses (20%). Toxicity included alopecia, nausea and vomiting, myelosuppression, infection, reduction in renal function and disturbance of consciousness. These data indicate that IFX is highly active in cervix cancer and, in combination with bleomycin and cisplatin, can be used for effective palliation and cytoreduction in greater than 70% of patients. IFX-containing regimens have potential for use as neoadjuvant and adjuvant therapy in patients at high risk of recurrence with conventional treatment. These hypotheses are currently being tested in prospective randomised trials.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0344-5704
pubmed:author
pubmed:issnType
Print
pubmed:volume
26 Suppl
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S12-6
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed:year
1990
pubmed:articleTitle
Phase II studies of ifosfamide alone and in combination in cancer of the cervix.
pubmed:affiliation
West Midlands Cancer Research Campaign Clinical Trials Unit, Queen Elizabeth Hospital, Edgbaston, Birmingham, United Kingdom.
pubmed:publicationType
Journal Article